Hormone receptor–positive early breast cancer has entered an era in which treatment decisions are increasingly shaped by biological risk, rather than menopausal status alone. A new systematic review and meta-analysis of phase III clinical trials has examined whether menopausal status changes the effectiveness of adjuvant CDK4/6 inhibitors, a class of targeted medicines designed to prevent cancer cells from progressing through the cell cycle. The analysis focuses on patients whose tumors express estrogen and/or progesterone receptors, a group that represents the majority of breast cancers worldwide and is commonly treated with long-term endocrine therapy.
CDK4/6 inhibitors work by blocking cyclin-dependent kinases 4 and 6, enzymes that help drive cells from the G1 phase of the cell cycle into the DNA-replication phase. In hormone receptor–positive breast cancer, estrogen signaling can stimulate this cellular transition, allowing malignant cells to multiply even after surgery. By inhibiting CDK4/6 activity, drugs such as abemaciclib and ribociclib aim to reinforce the growth-suppressive effects of endocrine therapy. Their use after surgery is intended to eliminate microscopic residual disease and reduce the likelihood that cancer will return in the breast, nearby lymph nodes or distant organs.
The question of menopausal status is clinically important because premenopausal and postmenopausal patients do not receive identical endocrine treatment. Premenopausal patients may require ovarian-function suppression, using medication or surgery to reduce estrogen production, while postmenopausal patients generally receive aromatase inhibitors or other endocrine therapies without deliberate ovarian suppression. These biological and treatment differences have raised the possibility that CDK4/6 inhibitors might produce different benefits in the two groups. The new analysis brings together evidence from large randomized phase III trials to determine whether menopausal status modifies the treatment effect or simply reflects differences in the underlying risk and management of the disease.
The trials included in this research program evaluated several strategies for adding CDK4/6 inhibition to standard adjuvant endocrine therapy. The monarchE study investigated abemaciclib in patients with hormone receptor–positive, HER2-negative disease considered at high risk of recurrence, particularly those with extensive lymph-node involvement or other aggressive tumor features. The NATALEE trial assessed ribociclib in a broader population of patients with stage II or III disease, including some whose risk characteristics were less severe. Other major studies, including PALLAS and PENELOPE-B, examined palbociclib in different early-breast-cancer settings. Although their designs and patient populations varied, together these trials provide one of the most extensive datasets available for evaluating targeted therapy across menopausal groups.
The central endpoint in these studies was invasive disease-free survival, which measures the time until a patient experiences a new invasive breast cancer, a recurrence in the original or another location, a distant metastasis, or death from any cause. This endpoint is especially relevant in early breast cancer because the purpose of adjuvant therapy is prevention: patients have already undergone surgery and may have no detectable disease, but microscopic cancer cells can remain dormant and later reappear. The meta-analysis compares treatment and control groups within menopausal subgroups and examines whether the relative reduction in recurrence is statistically different between premenopausal and postmenopausal patients.
The overall message from the evidence is that menopausal status does not appear to eliminate the benefit of adjuvant CDK4/6 inhibition when these agents are added to appropriate endocrine therapy. Across the phase III evidence, both premenopausal and postmenopausal patients experienced reductions in recurrence risk in trials that demonstrated a positive treatment effect. The magnitude of benefit varied between individual studies, reflecting differences in drug, duration of treatment, eligibility criteria, tumor risk and endocrine backbone. However, the available comparisons do not indicate a reliable biological interaction in which the drugs work only, or substantially better, in one menopausal group. Instead, the findings support the principle that treatment benefit is primarily linked to tumor biology and baseline recurrence risk.
That conclusion does not mean that menopausal status is irrelevant to clinical care. Premenopausal patients may face more complex treatment pathways because ovarian suppression can influence drug selection, tolerability and adherence. Hot flashes, sexual symptoms, bone loss, fatigue and changes in mood can become more pronounced when ovarian suppression is combined with endocrine therapy and a CDK4/6 inhibitor. Postmenopausal patients may have different vulnerabilities, including cardiovascular disease, metabolic conditions or pre-existing bone fragility. These factors can influence whether a patient is able to complete the recommended duration of therapy. The meta-analysis therefore supports comparable efficacy across groups, but it does not remove the need for individualized safety assessments and shared decision-making.
The findings also highlight why relative and absolute treatment effects must be interpreted together. A similar relative reduction in recurrence can translate into a larger absolute benefit for patients whose untreated risk is high. Someone with extensive lymph-node involvement or a large, biologically aggressive tumor has more opportunities for adjuvant therapy to prevent a future event than someone whose baseline risk is already low. This distinction helps explain why current treatment guidelines generally prioritize CDK4/6 inhibitors for carefully selected patients with higher-risk hormone receptor–positive, HER2-negative early breast cancer. Menopausal status may affect the practical delivery of therapy, but it should not be used as a substitute for a complete assessment of pathological and molecular risk.
Safety remains a major part of the clinical equation. CDK4/6 inhibitors are not interchangeable, and their adverse-effect profiles differ. Abemaciclib is associated with diarrhea, fatigue and liver-enzyme abnormalities, while ribociclib can cause neutropenia and requires attention to liver function and cardiac electrical activity, measured through the QT interval. Palbociclib commonly causes neutropenia, although its lack of demonstrated benefit in some adjuvant trials has helped shape current clinical practice. Monitoring blood counts, liver tests and other relevant parameters is necessary, and treatment interruptions or dose reductions may be required. Because adjuvant therapy is administered to patients who may already be cured by surgery and endocrine therapy alone, any recurrence reduction must be weighed against treatment toxicity, quality-of-life effects and financial burden.
The systematic review also exposes the limitations of comparing menopausal subgroups across trials. Menopausal status is not always defined identically, particularly in younger patients receiving ovarian suppression or chemotherapy-induced changes in ovarian function. Trial populations can differ in age, tumor stage, nodal burden, receptor expression, endocrine treatment and follow-up duration. In addition, subgroup analyses are often less statistically powerful than the primary trial comparisons, making it difficult to detect modest differences between groups. The investigators’ synthesis is therefore most useful as evidence that there is no convincing reason to withhold an effective adjuvant CDK4/6 inhibitor solely because a patient is premenopausal or postmenopausal. It is less capable of determining which specific drug, treatment duration or endocrine combination is optimal for every individual.
For patients and clinicians, the practical implication is a shift away from menopausal status as a decisive gatekeeper and toward integrated risk assessment. The most relevant questions include whether the cancer is HER2-negative, how many lymph nodes are involved, what the tumor grade and size are, whether other pathological features suggest endocrine resistance, and which endocrine regimen can be tolerated over time. Premenopausal patients should receive a clear plan for ovarian suppression and monitoring, while postmenopausal patients require assessment of bone health, cardiovascular risk and medication interactions. The emerging evidence suggests that CDK4/6 inhibitors can provide recurrence protection across the menopausal spectrum, but the decision to use them must remain anchored in absolute benefit, toxicity, patient preference and the biological behavior of the tumor. As longer follow-up becomes available, future analyses may clarify whether menopausal status influences late recurrence, treatment persistence or the size of the long-term survival advantage.
Subject of Research: The impact of menopausal status on the efficacy of adjuvant CDK4/6 inhibitors in hormone receptor–positive early breast cancer
Article Title: The impact of menopausal status on the efficacy of adjuvant CDK4/6 inhibitors in hormone receptor–positive early breast cancer: a systematic review and meta-analysis of phase III clinical trials
Article References: Phase III adjuvant CDK4/6 inhibitor trials, including monarchE, NATALEE, PALLAS and PENELOPE-B
Image Credits: AI Generated
DOI: 10.1007/s10549-026-08056-7
Keywords: Breast cancer, hormone receptor–positive breast cancer, early breast cancer, CDK4/6 inhibitors, abemaciclib, ribociclib, palbociclib, menopausal status, endocrine therapy, adjuvant treatment, disease-free survival, meta-analysis
